IL18R1

Across TCGA pan-cancer cohorts, IL18R1 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated IL18R1 data layer compared with 27 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher IL18R1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated IL18R1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and UCEC show a favorable association.

PDAC, UCEC, and LUAD are the cancer types where IL18R1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.865	0.349	.006	15	view →
UCEC	DFS	Median	II,III,IV	0.914	0.608	.040	12	view →
LUAD	DFS	Median	III,IV	0.438	1.000	.016	8	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

IL18R1–PDAC (DFS)

Open the PDAC breakdown →